Dr
Robert
Weinert-Aplin

Patent Attorney

London Office

Engineering

Telephone. +44(0) 207 776 5100
Email. [email protected]

Experience

Working primarily with private individuals, start-ups, SMEs and Universities, Rob has experience working across a wide range of technical areas and with clients from a variety of backgrounds. He is responsible for drafting and prosecuting UK, European and International patent applications and has particular experience in handling patent in the areas of medical devices, robotic vehicles, fluid pumping and control systems and construction technologies.

Rob is always interested to learn about new ideas, and particularly enjoys discussing how these can be developed into a commercial offering that will differentiate these new products and services from those that already exist.

Rob believes understanding what each client's business aims are and how their technology impacts this, is core to providing an IP strategy that is sustainable for the business in the long term.

Qualifications

Patent Attorney

Chartered (UK)
European


MENG

Biomedical Engineering

PHD

Clinical Medicine Research

POSTGRADUATE DIPLOMA OR CERTIFICATE

Intellectual Property Law

Publications

Tarilian Laser Technologies - a case study in due diligence

View publication online

Conferences: 2022

March 10th 2022

Manufacturing & Supply Chain Conference 2022

Speaker

Event details

CSR

Rob is a tutor for trainees preparing to sit the Advanced IP Law and Practice paper (FD1/P2) as part of HGF’s in-house tutorial scheme.

Related News

Artificial intelligence inventions in healthcare – can you patent them in Europe?

Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …

Read article

Patenting digital mental health

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder [1]. …

Read article

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 10th May 2022

HGF UPC events in Germany and Austria 2022

HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …

Event details
Event - 19th May 2022

HGF Complete webinar: comparison of registered and unregistered design rights procedures before the EUIPO and UKIPO

HGF is hosting a series of HGF Complete webinars this Spring. Our expert speakers will discuss trade marks and designs in the EU and the UK. We will compare and …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.